MCID: PRP021
MIFTS: 53

Peripheral Nervous System Neoplasm

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Peripheral Nervous System Neoplasm

MalaCards integrated aliases for Peripheral Nervous System Neoplasm:

Name: Peripheral Nervous System Neoplasm 12 14
Peripheral Nervous System Neoplasms 41 69
Nerve Sheath Neoplasm 12 72
Nerve Sheath Tumors 12 69
Neoplasm of Peripheral Nerve 12
Nerve Sheath Neoplasms 41
Tumor of Pns 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1192
NCIt 46 C3321 C4972

Summaries for Peripheral Nervous System Neoplasm

Disease Ontology : 12 A nervous system cancer that is located in the peripheral nervous system.

MalaCards based summary : Peripheral Nervous System Neoplasm, also known as peripheral nervous system neoplasms, is related to malignant peripheral nerve sheath tumor and autonomic nervous system neoplasm, and has symptoms including neuralgia An important gene associated with Peripheral Nervous System Neoplasm is MYCN (MYCN Proto-Oncogene, BHLH Transcription Factor), and among its related pathways/superpathways are ERK Signaling and Endometrial cancer. The drugs Dopamine and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include the peripheral nervous system, brain and bone, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 72 A nerve sheath tumor is a type of tumor of the nervous system (nervous system neoplasm) which is made up... more...

Related Diseases for Peripheral Nervous System Neoplasm

Diseases related to Peripheral Nervous System Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 86)
# Related Disease Score Top Affiliating Genes
1 malignant peripheral nerve sheath tumor 30.5 CD34 NF1 TP53
2 autonomic nervous system neoplasm 29.9 AKT1 ALK BACE1 CASP3 CNTN6 ENO2
3 malignant cardiac peripheral nerve sheath neoplasm 12.1
4 malignant triton tumor 11.1
5 gliofibroma 10.7 NF1 TP53
6 parameningeal embryonal rhabdomyosarcoma 10.7 ALK TP53
7 neuropathy, hereditary sensory and autonomic, type v 10.6 NGF NTRK1
8 optic nerve neoplasm 10.6 ENO2 NF1 TP53
9 adult medulloblastoma 10.6 ENO2 MYCN TP53
10 cerebral neuroblastoma 10.6 ENO2 NGF TP53
11 juvenile pilocytic astrocytoma 10.6 ENO2 NF1 TP53
12 meningeal melanomatosis 10.6 ENO2 NGF TP53
13 prolactin producing pituitary tumor 10.6 NGF NTRK1 TP53
14 optic nerve glioma 10.6 ENO2 NF1 TP53
15 bone ewing's sarcoma 10.6 ENO2 MYC MYCN
16 cellular neurofibroma 10.6 CD34 TP53
17 plexiform schwannoma 10.6 CD34 ENO2 NF1
18 intravascular fasciitis 10.6 ALK CD34
19 ovary sarcoma 10.6 CD34 MYC
20 ovarian angiosarcoma 10.6 CD34 MYC
21 infratentorial cancer 10.6 MYC MYCN TP53
22 short-rib thoracic dysplasia 4 with or without polydactyly 10.5 CASP3 TP53
23 cellular schwannoma 10.5 CD34 NF1 TP53
24 hereditary sensory neuropathy 10.5 NGF NTRK1 NTRK2
25 liver angiosarcoma 10.5 CD34 ENO2 TP53
26 lung meningioma 10.5 CD34 ENO2
27 adrenal neuroblastoma 10.5 ENO2 MYCN
28 primary effusion lymphoma 10.5 AKT1 CASP3 MYC
29 ganglioneuroblastoma 10.5 ENO2 MYCN NTRK1 NTRK2
30 integumentary system cancer 10.5 AKT1 ENO2 TP53
31 ganglioneuroma 10.5 ENO2 MYCN NTRK1 NTRK2
32 clear cell ependymoma 10.5 CD34 ENO2 TP53
33 intraneural perineurioma 10.5 ALK CD34 NF1
34 pharynx cancer 10.5 AKT1 CASP3 TP53
35 cerebral primitive neuroectodermal tumor 10.5 ENO2 MYC MYCN TP53
36 medullomyoblastoma 10.5 ENO2 MYC MYCN TP53
37 nodular ganglioneuroblastoma 10.5 ALK ENO2 MYCN NTRK2
38 muscle cancer 10.5 CD34 ENO2 TP53
39 peripheral nervous system disease 10.5 MFRP NGF PHOX2B
40 sensory system cancer 10.5 AKT1 MYC TP53
41 small cell cancer of the lung 10.5 ENO2 MYC MYCN TP53
42 rhabdomyosarcoma 2 10.5 ALK ENO2 MYCN TH
43 meninges sarcoma 10.5 CD34 TP53
44 status epilepticus 10.5 CASP3 ENO2 NTRK2
45 differentiated thyroid carcinoma 10.5 ALK NTRK1 TP53
46 rhabdomyosarcoma 10.5 ALK ENO2 MYCN TP53
47 organ system benign neoplasm 10.5 CD34 ENO2 NF1 TP53
48 ovarian cancer 1 10.5 AKT1 CASP3 TP53
49 deafness, autosomal recessive 74 10.5 BACE1 CASP3
50 endocrine gland cancer 10.5 AKT1 ENO2 TP53

Graphical network of the top 20 diseases related to Peripheral Nervous System Neoplasm:



Diseases related to Peripheral Nervous System Neoplasm

Symptoms & Phenotypes for Peripheral Nervous System Neoplasm

UMLS symptoms related to Peripheral Nervous System Neoplasm:


neuralgia

GenomeRNAi Phenotypes related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.47 AKT1 ALK MYC NF1 NTRK2
2 Decreased viability GR00221-A-2 9.47 AKT1 NF1 NTRK2
3 Decreased viability GR00221-A-3 9.47 AKT1 MYC
4 Decreased viability GR00221-A-4 9.47 AKT1 ALK NF1 NTRK2

MGI Mouse Phenotypes related to Peripheral Nervous System Neoplasm:

43 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.51 ALK BACE1 AKT1 CASP3 NF1 MYCN
2 growth/size/body region MP:0005378 10.46 ALK BACE1 AKT1 CASP3 NF1 MYCN
3 cellular MP:0005384 10.39 CASP3 CD34 BACE1 AKT1 MYC NF1
4 nervous system MP:0003631 10.39 BACE1 AKT1 CASP3 ALK MYCN CNTN6
5 mortality/aging MP:0010768 10.37 ALK BACE1 AKT1 CASP3 MYC NF1
6 homeostasis/metabolism MP:0005376 10.35 CASP3 ALK CD34 BACE1 AKT1 MYC
7 integument MP:0010771 10.26 ALK CD34 BACE1 AKT1 CASP3 NF1
8 normal MP:0002873 10.15 BACE1 AKT1 NF1 MYCN MYC NUMBL
9 muscle MP:0005369 10.13 CASP3 BACE1 AKT1 MYC NF1 MYCN
10 craniofacial MP:0005382 10.11 CASP3 MYC ENO2 MYCN NF1 NFIC
11 hearing/vestibular/ear MP:0005377 10.09 CASP3 MYC NF1 NUMBL NTRK1 NTRK2
12 liver/biliary system MP:0005370 10.05 AKT1 MYC MYCN NF1 NTRK2 TH
13 no phenotypic analysis MP:0003012 10.01 CASP3 BACE1 MYC MYCN NGF NTRK1
14 neoplasm MP:0002006 10 ALK CD34 AKT1 MYC NF1 TP53
15 reproductive system MP:0005389 9.91 CASP3 ALK AKT1 MYC MYCN NUMBL
16 pigmentation MP:0001186 9.87 ALK CASP3 MYC NF1 MFRP NTRK1
17 respiratory system MP:0005388 9.85 ALK AKT1 CASP3 NF1 MYCN ENO2
18 skeleton MP:0005390 9.61 CASP3 ALK AKT1 MYC MYCN NF1
19 vision/eye MP:0005391 9.36 ALK CASP3 NF1 MYCN MFRP NTRK1

Drugs & Therapeutics for Peripheral Nervous System Neoplasm

Drugs for Peripheral Nervous System Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 198)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
2
Methylphenidate Approved, Investigational Phase 4 20748-11-2, 113-45-1 4158
3 Anti-Infective Agents Phase 4,Phase 2,Phase 1,Early Phase 1
4 Central Nervous System Stimulants Phase 4
5 Dopamine Agents Phase 4
6 Dopamine Uptake Inhibitors Phase 4
7 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
8 Neurotransmitter Uptake Inhibitors Phase 4
9 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
10 Gentamicins Phase 4
11
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
12
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
13
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
14
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
15
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 38904 498142
16
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
17
Chlorhexidine Approved, Vet_approved Phase 2, Phase 3 55-56-1 2713 9552079
18
Lamotrigine Approved, Investigational Phase 2, Phase 3 84057-84-1 3878
19
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
20
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
21 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
22 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 1,Early Phase 1
23 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1
24 Isophosphamide mustard Phase 3,Phase 2 0
25 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
26 Anticonvulsants Phase 2, Phase 3,Phase 1
27 Imatinib Mesylate Phase 2, Phase 3,Phase 1 123596
28 calcium channel blockers Phase 2, Phase 3
29 Calcium, Dietary Phase 2, Phase 3
30 Chlorhexidine gluconate Phase 2, Phase 3
31 Diuretics, Potassium Sparing Phase 2, Phase 3
32 Excitatory Amino Acid Antagonists Phase 2, Phase 3
33 Excitatory Amino Acids Phase 2, Phase 3
34 Sodium Channel Blockers Phase 2, Phase 3
35
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
36
Peginterferon alfa-2b Approved Phase 2,Phase 1 215647-85-1, 99210-65-8
37
Vincristine Approved, Investigational Phase 2,Phase 1 2068-78-2, 57-22-7 5978
38
Diclofenac Approved, Vet_approved Phase 2 15307-86-5 3033
39
Everolimus Approved Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
40
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
41
Sirolimus Approved, Investigational Phase 2,Phase 1,Early Phase 1 53123-88-9 46835353 6436030 5284616
42
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
43
Sorafenib Approved, Investigational Phase 2,Phase 1 284461-73-0 216239 406563
44
Pirfenidone Approved, Investigational Phase 2,Phase 1 53179-13-8 40632
45
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
46
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
47
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
48
Romidepsin Approved, Investigational Phase 2,Phase 1 128517-07-7 5352062
49
Oxaliplatin Approved, Investigational Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
50
Irinotecan Approved, Investigational Phase 2,Phase 1 97682-44-5, 100286-90-6 60838

Interventional clinical trials:

(show top 50) (show all 224)

# Name Status NCT ID Phase Drugs
1 NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate Completed NCT00169611 Phase 4 methylphenidate
2 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
3 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Recruiting NCT02379754 Phase 4 Gentamicins
4 First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous Neurofibromas Unknown status NCT00921037 Phase 2, Phase 3
5 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3
6 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain Recruiting NCT02471339 Phase 3
8 Effect of Lamotrigine on Cognition in NF1 Recruiting NCT02256124 Phase 2, Phase 3 Lamotrigine;Placebo
9 Vestibular Schwannoma - Radiosurgery or Expectation: V-REX. Recruiting NCT02249572 Phase 2, Phase 3
10 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
11 Cyberknife Radiosurgery for Patients With Neurinomas Recruiting NCT02055859 Phase 3
12 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
13 Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma Withdrawn NCT01260103 Phase 3 Temozolomide;ANP Therapy
14 Medical Treatment of "High-Risk" Neurofibromas Unknown status NCT00846430 Phase 2 Peg-Interferon alpha-2b;Celecoxib (Celebrex);Temozolomide (temodar);Vincristine Sulfate (Oncovin)
15 Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1 Completed NCT03090971 Phase 2 Diclofenac Sodium;Saline Solution
16 Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T Completed NCT02332902 Phase 2 Everolimus
17 Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT02104323 Phase 2 Endostatin
18 Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Completed NCT01673009 Phase 2 Gleevec
19 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
20 Study of PEG-Intron for Plexiform Neurofibromas Completed NCT00396019 Phase 2 PEG-Intron
21 Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients Completed NCT01490476 Phase 2 RAD001
22 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2 Everolimus (RAD001) , Afinitor®
23 Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas Completed NCT01412892 Phase 2 RAD001: Everolimus
24 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
25 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
26 Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas Completed NCT01140360 Phase 1, Phase 2 Gleevec
27 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT00973739 Phase 2 Lapatinib
28 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
29 Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1 Completed NCT00754780 Phase 2 Pirfenidone
30 Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy Completed NCT00679354 Phase 2 cilengitide
31 A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas Completed NCT00634270 Phase 2 Sirolimus
32 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed NCT00589784 Phase 2 Sunitinib
33 S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor Completed NCT00068367 Phase 2 erlotinib hydrochloride
34 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
35 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
36 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
37 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
38 Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas Completed NCT00076102 Phase 2 Pirfenidone
39 Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma Completed NCT00070525 Phase 2 tipifarnib
40 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
41 Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas Completed NCT00030264 Phase 2 Methotrexate;Vinblastine
42 Antineoplaston Therapy in Treating Children With Visual Pathway Glioma Completed NCT00003477 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
43 R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas Completed NCT00021541 Phase 2 tipifarnib
44 Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 Completed NCT00004437 Phase 2
45 Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02986919 Phase 2 CPI-0610
46 Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas Recruiting NCT03231306 Phase 2 Binimetinib
47 A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery Recruiting NCT02691026 Phase 2 Pembrolizumab
48 PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02584647 Phase 1, Phase 2 PLX3397;Sirolimus
49 RGD PET/MRI in Sporadic Vestibular Schwannoma Recruiting NCT03393689 Phase 2 One injection of 68Ga-NODAGA-E[c(RGDyK)]2
50 Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers Recruiting NCT03215511 Phase 1, Phase 2 LOXO-195

Search NIH Clinical Center for Peripheral Nervous System Neoplasm

Cochrane evidence based reviews: peripheral nervous system neoplasms

Genetic Tests for Peripheral Nervous System Neoplasm

Anatomical Context for Peripheral Nervous System Neoplasm

The Foundational Model of Anatomy Ontology organs/tissues related to Peripheral Nervous System Neoplasm:

18
The Peripheral Nervous System

MalaCards organs/tissues related to Peripheral Nervous System Neoplasm:

38
Brain, Bone, T Cells, Spinal Cord, Skin

Publications for Peripheral Nervous System Neoplasm

Articles related to Peripheral Nervous System Neoplasm:

# Title Authors Year
1
Diagnostic implications of podoplanin expression in peripheral nerve sheath neoplasms. ( 18480004 )
2008
2
Perineurioma: a distinctive and underrecognized peripheral nerve sheath neoplasm. ( 17425397 )
2007
3
Perineurioma of the finger: case report of a rare peripheral nerve sheath neoplasm of pure perineurial cell lineage. ( 9556280 )
1998
4
Human peripheral nerve sheath neoplasm: expression of Schwann cell-related markers and their relation to malignant transformation. ( 1656253 )
1991

Variations for Peripheral Nervous System Neoplasm

Expression for Peripheral Nervous System Neoplasm

Search GEO for disease gene expression data for Peripheral Nervous System Neoplasm.

Pathways for Peripheral Nervous System Neoplasm

Pathways related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.78 AKT1 ALK CASP3 MYC NF1 NGF
2
Show member pathways
13 AKT1 ALK CASP3 MYC NF1 NTRK1
3
Show member pathways
12.92 AKT1 CASP3 MYC NGF NTRK1 NTRK2
4 12.81 AKT1 ALK CASP3 MYC NTRK1 TP53
5
Show member pathways
12.78 AKT1 CASP3 MYC NGF NTRK1 TP53
6
Show member pathways
12.69 AKT1 NF1 NGF NTRK1 NTRK2
7
Show member pathways
12.67 AKT1 CASP3 NGF NTRK1 NTRK2 TP53
8
Show member pathways
12.44 AKT1 CASP3 MYC TP53
9
Show member pathways
12.41 AKT1 CASP3 NTRK1 NTRK2 TP53
10 12.25 AKT1 CASP3 MYC TP53
11 12.22 AKT1 CASP3 MYC NF1 NGF NTRK1
12 12.2 MYC MYCN NTRK1 TP53
13 12.15 AKT1 CASP3 MYC TP53
14 12.12 CASP3 NGF NTRK2 PHOX2B TH
15 12.08 AKT1 CASP3 MYC NF1 TP53
16
Show member pathways
12.05 AKT1 CASP3 MFRP MYC NTRK1 NTRK2
17 12.01 AKT1 CASP3 NGF NTRK1 NTRK2
18 11.93 AKT1 MYC NF1 TP53
19 11.84 AKT1 CASP3 MYC TP53
20
Show member pathways
11.81 AKT1 CASP3 MYC NGF NTRK1 TP53
21 11.76 BACE1 ENO2 MYCN NF1 NGF NTRK1
22 11.69 AKT1 CASP3 TP53
23
Show member pathways
11.66 AKT1 CASP3 NGF TP53
24 11.64 AKT1 MYC NTRK1 TP53
25
Show member pathways
11.6 NGF NTRK1 NTRK2
26 11.51 AKT1 BACE1 CASP3 TP53
27 11.47 AKT1 CNTN6 MYC MYCN TP53
28 11.45 BACE1 NTRK1 NTRK2
29 11.41 AKT1 CASP3 MYC TP53
30 11.33 AKT1 CASP3 MYC TP53
31 11.29 AKT1 CASP3 NGF
32 10.81 CASP3 NTRK2
33
Show member pathways
10.65 NGF NTRK1 NTRK2
34 10.32 MYC MYCN

GO Terms for Peripheral Nervous System Neoplasm

Biological processes related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 nervous system development GO:0007399 9.99 AKT1 ALK CNTN6 NTRK1 NTRK2 NUMBL
2 cell proliferation GO:0008283 9.98 AKT1 ALK CD34 MYC TP53
3 positive regulation of apoptotic process GO:0043065 9.97 AKT1 CASP3 NF1 NGF TP53
4 negative regulation of apoptotic process GO:0043066 9.95 AKT1 CASP3 MYC NGF NTRK1 TP53
5 negative regulation of gene expression GO:0010629 9.93 AKT1 CD34 MYC MYCN
6 response to drug GO:0042493 9.93 CASP3 MYC NTRK1 TH TP53
7 protein autophosphorylation GO:0046777 9.89 AKT1 ALK NTRK1 NTRK2
8 wound healing GO:0042060 9.82 CASP3 NF1 TP53
9 cellular response to organic cyclic compound GO:0071407 9.81 AKT1 CASP3 MYC
10 cerebral cortex development GO:0021987 9.8 NF1 NTRK2 TH
11 neuron differentiation GO:0030182 9.8 CASP3 CNTN6 NTRK2 PHOX2B
12 cellular response to drug GO:0035690 9.79 MYC TH TP53
13 cellular response to growth factor stimulus GO:0071363 9.77 AKT1 NTRK1 TH
14 negative regulation of neuron death GO:1901215 9.75 AKT1 CD34 NTRK1
15 positive regulation of neuron apoptotic process GO:0043525 9.73 CASP3 NF1 TP53
16 response to nicotine GO:0035094 9.7 CASP3 NTRK1 TH
17 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.67 ALK NGF NTRK1 NTRK2
18 negative regulation of astrocyte differentiation GO:0048712 9.64 MYCN NF1
19 positive regulation of gene expression GO:0010628 9.63 CD34 MYC MYCN NGF NTRK2 TP53
20 positive regulation of mitochondrial membrane potential GO:0010918 9.62 AKT1 MYC
21 response to ethanol GO:0045471 9.62 MYC NTRK1 TH TP53
22 cellular response to nicotine GO:0071316 9.61 NTRK1 TH
23 response to gamma radiation GO:0010332 9.61 MYC TP53 TRIM13
24 negative regulation of fibroblast proliferation GO:0048147 9.58 MYC NF1 TP53
25 mechanoreceptor differentiation GO:0042490 9.55 NTRK1 NTRK2
26 neurotrophin signaling pathway GO:0038179 9.46 NTRK1 NTRK2
27 response to metal ion GO:0010038 9.43 CASP3 TH TP53
28 sympathetic nervous system development GO:0048485 9.13 NF1 NTRK1 PHOX2B
29 neurotrophin TRK receptor signaling pathway GO:0048011 8.8 CASP3 NGF NTRK1

Molecular functions related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 ALK NTRK1 NTRK2
2 neurotrophin binding GO:0043121 8.96 NTRK1 NTRK2
3 neurotrophin receptor activity GO:0005030 8.62 NTRK1 NTRK2

Sources for Peripheral Nervous System Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....